Cargando…

mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancer

Delta-human epidermal growth factor receptor 2 (HER2) is a splice variant of HER2, which lacks 16 amino acids in the extracellular domain. The aim of the present study was to elucidate the expression of delta-HER2 and its clinicopathological correlation in Japanese patients with HER2-overexpressing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wada, Ryuichi, Yagihashi, Soroku, Naito, Zenya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355676/ https://www.ncbi.nlm.nih.gov/pubmed/27840986 http://dx.doi.org/10.3892/mmr.2016.5892

Ejemplares similares

HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women
por: Aman, Nguiessan Alphonse, et al.
Publicado: (2019)

Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer
por: Shu, Lan, et al.
Publicado: (2022)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
por: Li, Xin, et al.
Publicado: (2018)

Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics
por: Liu, Xiangdong, et al.
Publicado: (2015)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
por: Dent, S., et al.
Publicado: (2009)

Breast Cancer With a HER2 IHC2+ and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number <4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event
por: Liu, Yuanyuan, et al.
Publicado: (2020)

HER2 c-Terminal Fragments Are Expressed via Internal Translation of the HER2 mRNA
por: Godfrey, Jack D., et al.
Publicado: (2022)

Impact of Serum HER2 Levels on Survival and Its Correlation with Clinicopathological Parameters in Women with Breast Cancer
por: Ryu, Dong Won, et al.
Publicado: (2012)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
por: Zhou, Shuling, et al.
Publicado: (2022)

Evaluation of HER2 Positivity Based on Clinicopathological Findings in HER2 Borderline Tumors in Iranian Patients with Breast Cancer
por: Omranipour, Ramesh, et al.
Publicado: (2023)

Overexpression of HER2/HER3 and clinical feature of ovarian cancer
por: Chung, Ye Won, et al.
Publicado: (2019)

Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade
por: Batalha, Sofia, et al.
Publicado: (2023)

Correlation between HER2 Overexpression and Clinicopathological Characteristics in Gastric Cancer Patients Who Have Undergone Curative Resection
por: Son, Ho Sung, et al.
Publicado: (2014)

Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis
por: Wu, Sheng-wen, et al.
Publicado: (2015)

Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast
por: Jang, Yunjeong, et al.
Publicado: (2020)

Clinicopathological features and prognosis of patients with HER2-low breast cancer
por: Yang, Xin, et al.
Publicado: (2023)

Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer
por: Chen, Chih-Jung, et al.
Publicado: (2022)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
por: Bartsch, R, et al.
Publicado: (2012)

Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis
por: Yu, Qiuyan, et al.
Publicado: (2015)

HER2-Targeted Multifunctional Silica Nanoparticles Specifically Enhance the Radiosensitivity of HER2-Overexpressing Breast Cancer Cells
por: Yamaguchi, Haruka, et al.
Publicado: (2018)

Alterations in mRNA profiles of trastuzumab-resistant Her-2-positive breast cancer
por: Zhao, Bin, et al.
Publicado: (2018)

Evaluation of HER2/neu Expression in High-Grade Endometrial Carcinoma and Its Clinicopathological Correlation
por: Sarmadi, Soheila, et al.
Publicado: (2019)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2022)

A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
por: Reix, Nathalie, et al.
Publicado: (2016)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
por: Peckys, Diana B., et al.
Publicado: (2021)

Clinicopathological characteristics of HER2-low breast cancer: a retrospective study
por: Yang, Man, et al.
Publicado: (2023)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Towards comprehensive characterization of HER2 overexpression
por: Berezov, Alan, et al.
Publicado: (2006)

MicroRNA and HER2-overexpressing Cancer
por: Wang, Shizhen Emily, et al.
Publicado: (2013)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
por: Fiszman, Gabriel L., et al.
Publicado: (2011)

Optical imaging of metabolism in HER2 overexpressing breast cancer cells
por: Walsh, Alex, et al.
Publicado: (2011)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer
por: dos Santos, Giovana Tavares, et al.
Publicado: (2017)

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
por: Yang, Liu, et al.
Publicado: (2022)

HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features
por: He, Lin, et al.
Publicado: (2021)

Construction of differentially expressed Her-2 related lncRNA-mRNA-miRNA ceRNA network in Her-2 positive breast cancer
por: Jia, Xiaochen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i7jlvse8c57vqv529n63s3b29l